Cargando…

Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo

HM41322 is a novel oral sodium-glucose cotransporter (SGLT) 1/2 dual inhibitor. In this study, the in vitro and in vivo pharmacokinetic and pharmacologic profiles of HM41322 were compared to those of dapagliflozin. HM41322 showed a 10-fold selectivity for SGLT2 over SGLT1. HM41322 showed an inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Kyu Hang, Lee, Sang Don, Kim, Namdu, Suh, Kwee Hyun, Kim, Young Hoon, Sim, Sang Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Physiological Society and The Korean Society of Pharmacology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315097/ https://www.ncbi.nlm.nih.gov/pubmed/30627010 http://dx.doi.org/10.4196/kjpp.2019.23.1.55

Ejemplares similares

HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus
por: Kim, Yu-Yon, et al.
Publicado: (2017)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
por: Park, Jin Kyun, et al.
Publicado: (2016)

Applications of stable, nonradioactive isotope tracers in in vivo human metabolic research
por: Kim, Il-Young, et al.
Publicado: (2016)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism
por: Heo, Yong Ho, et al.
Publicado: (2022)

H.M. the Emperor of Ethiopia
por: CERN PhotoLab
Publicado: (1967)

ST-HM: not only cranes
por: Bertone, C
Publicado: (2002)

ST-HM equipment consolidation
por: Rühl, I, et al.
Publicado: (2003)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

The Relationship between Character Traits and In Vivo Cerebral Serotonin Transporter Availability in Healthy Subjects: A High-Resolution PET Study with C-11 DASB
por: Kim, Jeong-Hee, et al.
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Bio-conjugated nanoarchitectonics with dual-labeled nanoparticles for a colorimetric and fluorescent dual-mode serological lateral flow immunoassay sensor in detection of SARS-CoV-2 in clinical samples
por: Kim, Sang Ki, et al.
Publicado: (2023)

Alterations in the Genomic Distribution of 5hmC in In Vivo Aged Human Skin Fibroblasts
por: Kołodziej-Wojnar, Paulina, et al.
Publicado: (2020)

The case history of 'Sir H.M.'.
por: Longfield-Jones, G M
Publicado: (1988)

H.M. King George at Lincoln
Publicado: (1918)

H.M. Queen Alexandra's Letter
por: Alexandra,
Publicado: (1918)

SAT149 In Vitro Characterization Of A Novel Long-acting Glucagon Analog (HM15136) And Its Potential Effect In Animal Models Of Chronic Hypoglycemic Diseases
por: Kim, Jung Kuk, et al.
Publicado: (2023)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Technetium-99m HM-PAO SPECT in patients with delayed neurologic sequelae after carbon monoxide poisoning.
por: Choi, I. S., et al.
Publicado: (1992)

PEGylated crushed gold shell-radiolabeled core nanoballs for in vivo tumor imaging with dual positron emission tomography and Cerenkov luminescent imaging
por: Lee, Sang Bong, et al.
Publicado: (2018)

Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3′-shore
por: Park, Jong-Lyul, et al.
Publicado: (2015)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
por: Kim, So Ra, et al.
Publicado: (2020)

Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus
por: Lee, Kyuhyun, et al.
Publicado: (2023)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Hm-MyD88 and Hm-SARM: Two key regulators of the neuroimmune system and neural repair in the medicinal leech
por: Rodet, F., et al.
Publicado: (2015)

Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells
por: Kang, Mi Hyun, et al.
Publicado: (2016)

In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)
por: Liu, Zhendong, et al.
Publicado: (2011)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
por: Lee, Hyun Jung, et al.
Publicado: (2014)

Chromatin Changes Associated with Neuronal Maintenance and Their Pharmacological Application
por: Lee, Jang Ho, et al.
Publicado: (2018)

HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model
por: Zeng, Wu, et al.
Publicado: (2020)

Recent studies on betulinic acid and its biological and pharmacological activity
por: Lee, Sook Young, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g976f9dtme81o7lb2nqsf57cg2